Neurological Biomarkers Market By Type (Genomic, Proteomic, Metabolomic, Others), By Application (Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease): Global Opportunity Analysis and Industry Forecast, 2021-2031

Neurological Biomarkers Market

Ever-increasing rise in the incidence of Alzheimer’s and Parkinson’s is anticipated to contribute toward the robust growth of neurological biomarkers among these two applications. In addition, surge in adoption of neurological biomarkers in drug development and validation has increased over the years to improve the accuracy of clinical trials. Further, rise in transition toward personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimer’s and Parkinson’s.

Recent advancements in biomarkers, such as biomarker signatures are making neurological diseases more treatable. This has resulted in increase in noninvasive testing, boot to discovery and development of medicine using biomarkers, and early diagnosis of neurological diseases.  

However, the sales of neurological biomarkers product have witnessed hindrances, owing to the strict government regulations. The emerging ethical issues regarding early diagnosis of Alzheimer’s disease, Parkinson’s disease, and multiple Sclerosis is expected to impede the market growth. On the contrary, surge in healthcare investments in public as well as private sectors, increase in focus on developing cost-effective biomarker testing increase in patient population, and rise in demand for non-invasive diagnostic techniques for Alzheimer’s and Parkinson’s are anticipated to open new avenues for expansion of the neurological biomarkers market size during the forecast period.

Depending on product type, the genomic segment is expected to witness a significant CAGR during the forecast period in neurological biomarkers market analysis. The major factors that contribute toward the growth of the genomic biomarkers market include increase in prevalence of neurological diseases, rise in incidence rate of ischemic stroke, high demand for minimally invasive procedures, development of technologies in clinical laboratory tests, immense developments in infrastructure for data sharing and analysis such as bioinformatics, and growing awareness about genomics biomarker-based personalized medicines. The rise in development of personalized medicines based on a specific genetic sequence of individual is projected to help propel the growth of the genomic biomarker segment in neurological biomarkers Market.

On the basis of application of neurological biomarkers, the multiple sclerosis segment is expected to witness a significant CAGR during the forecast period. Rise in incidence rate of multiple sclerosis boot the growth of neurological biomarker market. For instance, according to National Multiple Sclerosis Society 2019, between 750,000 and 1 million people in the U.S. over the age of 18 are living with MS. There are more people living with MS in the Northeast and Midwest than in the South. The rates of MS have increased worldwide since 1955. The first report of MS in the U.S. was published in 1976 and found 123,00 cases. A study from 1990 found 300,000 cases of MS. This compares to the estimated 750,000 to 1 million cases in 2019.

On the basis of region, Asia-Pacific is expected to witness highest CAGR during the forecast period in neurological biomarkers market forecast, owing to rise in geriatric population and the launch of various products in the region to fulfill the growing demands. Additionally, the development of human-induced pluripotent stem cells (iPS) for early diagnosis of Parkinson’s disease in Japan is a recent trend, which is being followed. In addition, the rise in population in Japan is on an increase and the number has reached to 126.26 million individuals as of 2019. Therefore, such increase in population which is more susceptible to Parkinson’s disease is anticipated to help supplement the neurological biomarkers industry growth.

KEY FINDINGS OF THE STUDY

By product type, the proteomic segment held the largest share in the neurological biomarkers market share in 2021.

By application, the Alzheimer's disease segment held the largest share in the neurological biomarkers market trends in 2021, and is expected to remain dominant during the forecast period.

By region, North America held the largest market share in neurological biomarkers industry in 2021.

Overview

 

Neurological biomarkers are measurable indicators of biological state or condition of patients suffering from neurodegenerative diseases. Brain diseases require plenty of markers to reflect the metabolic impairment of different brain cells. The recent introduction of the metabolomic approach helps the study of neurological diseases based on profiling a multitude of biochemical components related to brain metabolism.

Major factors driving growth of the neurological biomarkers market include increase in geriatric population that are prone to neurological diseases, rise in head injuries, rise in prevalence of Alzheimer’s disease, Parkinson’s disease, and multiple Sclerosis. For instance, according to the latest WHO data published in 2020 Parkinson's disease deaths in Australia reached 2,036 or 1.49% of total deaths. The age adjusted Death Rate is 3.35 per 100,000 of population ranks Australia #131 in the world. According to WHO update 2022, globally, disability and death due to Parkinson’s disease are increasing faster than for any other neurological disorder.

For instance, according to National Multiple Sclerosis Society 2019, between 750,000 and 1 million people in the U.S. over the age of 18 are living with MS. There are more people living with MS in the Northeast and Midwest than in the South. The rates of MS have increased worldwide since 1955. The first report of MS in the U.S. was published in 1976 and found 123,00 cases. A study from 1990 found 300,000 cases of MS. This compares to the estimated 750,000 to 1 million cases in 2019.

Moreover, neurology is one of the disciplines where personalized medicine has been emerging as an important part of treatment methods for Alzheimer’s, Parkinson’s and Multiple Sclerosis. Neurological biomarkers find a varied scope in personalized medicine, which eventually spurs the demand for diagnosis by incorporating neurological biomarkers. Therefore, rise in the demand for personalized medicine boost the growth of neurological biomarkers market.

Furthermore, increase in demand for minimally invasive procedures propels the adoption of neurological biomarkers product. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the growth of the neurological biomarkers market. For instance, in June 2021, Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, announced a partnership with University of California, San Francisco (UCSF) and UC Berkeley to speed up the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS) such as Alzheimer’s, Parkinson’s, Huntington’s, Amyotrophic lateral sclerosis (ALS) and autism. UCSF and UC Berkeley had received up to $53 million from Genentech over the course of the 10-year collaboration.

However, the emerging ethical issues regarding early diagnosis of Alzheimer’s disease, Parkinson’s disease, and multiple Sclerosis is expected to impede the market growth. strict government regulations and high cost for neurological biomarkers products also restrain the market growth.

Furthermore, healthcare business is predicted to witness growth, owing increase in focus on developing cost-effective biomarker testing increase in patient population, and rise in demand for non-invasive diagnostic techniques for Alzheimer’s and Parkinson’s, increase in R&D investments in drug discovery & development, and rise in awareness regarding neurological biomarker. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The neurological biomarkers market is segmented on the basis of type, application, and region. On the basis of type, the market is classified into genomic, proteomic, metabolomic, and others. By application, the market is segregated into Alzheimer's disease, Parkinson's disease, and multiple sclerosis. 

Region wise, the market is analyzed across North America (the U.S., and Canada), Europe (Germany, France, the UK, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and Rest of LAMEA).

Major players profiled in the report are Biomérieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGAA, Myriad Genetics, Inc., Neurobio, Perkinelmer Inc., Quanterix, Shimadzu Corporation, Thermo Fisher Scientific, Inc.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the diabetic nephropathy market to identify the prevailing opportunities

This study presents the competitive landscape of the global market to predict the competitive environment across various regions

Comprehensive analysis of factors that drive and restrict the market growth is provided

Region & country wise analysis is provided to understand the market trends and dynamics

Key Market Segments

○ MYRIAD RBM (MYRIAD GENETICS, INC.

Scope of Neurological Biomarkers Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Genomic

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Proteomic

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Metabolomic

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Others

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Alzheimer's Disease

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Multiple Sclerosis

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Parkinson's Disease

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key trends and opportunities

6.2.2 North America Market size and forecast, by Type

6.2.3 North America Market size and forecast, by Application

6.2.4 North America Market size and forecast, by country

6.2.4.1 U.S.

6.2.4.1.1 Market size and forecast, by Type

6.2.4.1.2 Market size and forecast, by Application

6.2.4.2 Canada

6.2.4.2.1 Market size and forecast, by Type

6.2.4.2.2 Market size and forecast, by Application

6.3 Europe

6.3.1 Key trends and opportunities

6.3.2 Europe Market size and forecast, by Type

6.3.3 Europe Market size and forecast, by Application

6.3.4 Europe Market size and forecast, by country

6.3.4.1 Germany

6.3.4.1.1 Market size and forecast, by Type

6.3.4.1.2 Market size and forecast, by Application

6.3.4.2 France

6.3.4.2.1 Market size and forecast, by Type

6.3.4.2.2 Market size and forecast, by Application

6.3.4.3 UK

6.3.4.3.1 Market size and forecast, by Type

6.3.4.3.2 Market size and forecast, by Application

6.3.4.4 Rest of Europe

6.3.4.4.1 Market size and forecast, by Type

6.3.4.4.2 Market size and forecast, by Application

6.4 Asia-Pacific

6.4.1 Key trends and opportunities

6.4.2 Asia-Pacific Market size and forecast, by Type

6.4.3 Asia-Pacific Market size and forecast, by Application

6.4.4 Asia-Pacific Market size and forecast, by country

6.4.4.1 Japan

6.4.4.1.1 Market size and forecast, by Type

6.4.4.1.2 Market size and forecast, by Application

6.4.4.2 China

6.4.4.2.1 Market size and forecast, by Type

6.4.4.2.2 Market size and forecast, by Application

6.4.4.3 India

6.4.4.3.1 Market size and forecast, by Type

6.4.4.3.2 Market size and forecast, by Application

6.4.4.4 Rest of Asia-Pacific

6.4.4.4.1 Market size and forecast, by Type

6.4.4.4.2 Market size and forecast, by Application

6.5 LAMEA

6.5.1 Key trends and opportunities

6.5.2 LAMEA Market size and forecast, by Type

6.5.3 LAMEA Market size and forecast, by Application

6.5.4 LAMEA Market size and forecast, by country

6.5.4.1 Brazil

6.5.4.1.1 Market size and forecast, by Type

6.5.4.1.2 Market size and forecast, by Application

6.5.4.2 Saudi Arabia

6.5.4.2.1 Market size and forecast, by Type

6.5.4.2.2 Market size and forecast, by Application

6.5.4.3 Rest of LAMEA

6.5.4.3.1 Market size and forecast, by Type

6.5.4.3.2 Market size and forecast, by Application

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Key developments

8.1 F. HOFFMANN-LA ROCHE LTD.

8.1.1 Company overview

8.1.2 Company snapshot

8.1.3 Operating business segments

8.1.4 Product portfolio

8.1.5 Business performance

8.1.6 Key strategic moves and developments

8.2 Bio-Rad Laboratories, Inc.

8.2.1 Company overview

8.2.2 Company snapshot

8.2.3 Operating business segments

8.2.4 Product portfolio

8.2.5 Business performance

8.2.6 Key strategic moves and developments

8.3 merck kgaa, darmstadt, germany

8.3.1 Company overview

8.3.2 Company snapshot

8.3.3 Operating business segments

8.3.4 Product portfolio

8.3.5 Business performance

8.3.6 Key strategic moves and developments

8.4 PERKINELMER INC.

8.4.1 Company overview

8.4.2 Company snapshot

8.4.3 Operating business segments

8.4.4 Product portfolio

8.4.5 Business performance

8.4.6 Key strategic moves and developments

8.5 shimadzu corporation

8.5.1 Company overview

8.5.2 Company snapshot

8.5.3 Operating business segments

8.5.4 Product portfolio

8.5.5 Business performance

8.5.6 Key strategic moves and developments

8.6 Thermo Fisher Scientific, Inc.

8.6.1 Company overview

8.6.2 Company snapshot

8.6.3 Operating business segments

8.6.4 Product portfolio

8.6.5 Business performance

8.6.6 Key strategic moves and developments

8.7 Quanterix

8.7.1 Company overview

8.7.2 Company snapshot

8.7.3 Operating business segments

8.7.4 Product portfolio

8.7.5 Business performance

8.7.6 Key strategic moves and developments

8.8 Neurobio

8.8.1 Company overview

8.8.2 Company snapshot

8.8.3 Operating business segments

8.8.4 Product portfolio

8.8.5 Business performance

8.8.6 Key strategic moves and developments

8.9 bioMérieux

8.9.1 Company overview

8.9.2 Company snapshot

8.9.3 Operating business segments

8.9.4 Product portfolio

8.9.5 Business performance

8.9.6 Key strategic moves and developments

8.10 MYRIAD RBM (MYRIAD GENETICS, INC.)

8.10.1 Company overview

8.10.2 Company snapshot

8.10.3 Operating business segments

8.10.4 Product portfolio

8.10.5 Business performance

8.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 2. NEUROLOGICAL BIOMARKERS MARKET, FOR GENOMIC, BY REGION, 2021-2031 ($MILLION)

TABLE 3. NEUROLOGICAL BIOMARKERS MARKET FOR GENOMIC, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. NEUROLOGICAL BIOMARKERS MARKET, FOR PROTEOMIC, BY REGION, 2021-2031 ($MILLION)

TABLE 5. NEUROLOGICAL BIOMARKERS MARKET FOR PROTEOMIC, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. NEUROLOGICAL BIOMARKERS MARKET, FOR METABOLOMIC, BY REGION, 2021-2031 ($MILLION)

TABLE 7. NEUROLOGICAL BIOMARKERS MARKET FOR METABOLOMIC, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 8. NEUROLOGICAL BIOMARKERS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 9. NEUROLOGICAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 11. NEUROLOGICAL BIOMARKERS MARKET, FOR ALZHEIMER'S DISEASE, BY REGION, 2021-2031 ($MILLION)

TABLE 12. NEUROLOGICAL BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 13. NEUROLOGICAL BIOMARKERS MARKET, FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2031 ($MILLION)

TABLE 14. NEUROLOGICAL BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 15. NEUROLOGICAL BIOMARKERS MARKET, FOR PARKINSON'S DISEASE, BY REGION, 2021-2031 ($MILLION)

TABLE 16. NEUROLOGICAL BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 17. NEUROLOGICAL BIOMARKERS MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 18. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 19. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 20. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 21. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 22. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 23. CANADA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 24. CANADA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 25. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 26. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 27. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 28. GERMANY NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 29. GERMANY NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 30. FRANCE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 31. FRANCE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 32. UK NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 33. UK NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 34. REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 35. REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 36. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 37. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 38. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 39. JAPAN NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 40. JAPAN NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 41. CHINA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 42. CHINA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 43. INDIA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 44. INDIA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 45. REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 46. REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 47. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 48. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 49. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 50. BRAZIL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 51. BRAZIL NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 52. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 53. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 54. REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 55. REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 56.F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 57.F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS

TABLE 58.F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 59.F. HOFFMANN-LA ROCHE LTD.: NET SALES,

TABLE 60.F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES

TABLE 61.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT

TABLE 62.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS

TABLE 63.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO

TABLE 64.BIO-RAD LABORATORIES, INC.: NET SALES,

TABLE 65.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES

TABLE 66.MERCK KGAA, DARMSTADT, GERMANY: COMPANY SNAPSHOT

TABLE 67.MERCK KGAA, DARMSTADT, GERMANY: OPERATING SEGMENTS

TABLE 68.MERCK KGAA, DARMSTADT, GERMANY: PRODUCT PORTFOLIO

TABLE 69.MERCK KGAA, DARMSTADT, GERMANY: NET SALES,

TABLE 70.MERCK KGAA, DARMSTADT, GERMANY: KEY STRATERGIES

TABLE 71.PERKINELMER INC.: COMPANY SNAPSHOT

TABLE 72.PERKINELMER INC.: OPERATING SEGMENTS

TABLE 73.PERKINELMER INC.: PRODUCT PORTFOLIO

TABLE 74.PERKINELMER INC.: NET SALES,

TABLE 75.PERKINELMER INC.: KEY STRATERGIES

TABLE 76.SHIMADZU CORPORATION: COMPANY SNAPSHOT

TABLE 77.SHIMADZU CORPORATION: OPERATING SEGMENTS

TABLE 78.SHIMADZU CORPORATION: PRODUCT PORTFOLIO

TABLE 79.SHIMADZU CORPORATION: NET SALES,

TABLE 80.SHIMADZU CORPORATION: KEY STRATERGIES

TABLE 81.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT

TABLE 82.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS

TABLE 83.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO

TABLE 84.THERMO FISHER SCIENTIFIC, INC.: NET SALES,

TABLE 85.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES

TABLE 86.QUANTERIX: COMPANY SNAPSHOT

TABLE 87.QUANTERIX: OPERATING SEGMENTS

TABLE 88.QUANTERIX: PRODUCT PORTFOLIO

TABLE 89.QUANTERIX: NET SALES,

TABLE 90.QUANTERIX: KEY STRATERGIES

TABLE 91.NEUROBIO: COMPANY SNAPSHOT

TABLE 92.NEUROBIO: OPERATING SEGMENTS

TABLE 93.NEUROBIO: PRODUCT PORTFOLIO

TABLE 94.NEUROBIO: NET SALES,

TABLE 95.NEUROBIO: KEY STRATERGIES

TABLE 96.BIOMÉRIEUX: COMPANY SNAPSHOT

TABLE 97.BIOMÉRIEUX: OPERATING SEGMENTS

TABLE 98.BIOMÉRIEUX: PRODUCT PORTFOLIO

TABLE 99.BIOMÉRIEUX: NET SALES,

TABLE 100.BIOMÉRIEUX: KEY STRATERGIES

TABLE 101.MYRIAD RBM (MYRIAD GENETICS, INC.): COMPANY SNAPSHOT

TABLE 102.MYRIAD RBM (MYRIAD GENETICS, INC.): OPERATING SEGMENTS

TABLE 103.MYRIAD RBM (MYRIAD GENETICS, INC.): PRODUCT PORTFOLIO

TABLE 104.MYRIAD RBM (MYRIAD GENETICS, INC.): NET SALES,

TABLE 105.MYRIAD RBM (MYRIAD GENETICS, INC.): KEY STRATERGIES LIST OF FIGURES

FIGURE 1.NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION

FIGURE 2.NEUROLOGICAL BIOMARKERS MARKET,2021-2031

FIGURE 3.NEUROLOGICAL BIOMARKERS MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.NEUROLOGICAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.NEUROLOGICAL BIOMARKERS MARKET,BY TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PROTEOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF METABOLOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)

FIGURE 17.NEUROLOGICAL BIOMARKERS MARKET,BY APPLICATION,2021(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ALZHEIMER'S DISEASE NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MULTIPLE SCLEROSIS NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF PARKINSON'S DISEASE NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)

FIGURE 21.NEUROLOGICAL BIOMARKERS MARKET BY REGION,2021

FIGURE 22.U.S. NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 23.CANADA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 24.GERMANY NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 25.FRANCE NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 26.UK NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 27.REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 28.JAPAN NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 29.CHINA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 30.INDIA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 31.REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 32.BRAZIL NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 33.SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 34.REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)

FIGURE 35. TOP WINNING STRATEGIES, BY YEAR

FIGURE 36. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 37. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 38.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 39.COMPETITIVE DASHBOARD

FIGURE 40.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 41.F. HOFFMANN-LA ROCHE LTD..: NET SALES ,($MILLION)

FIGURE 42.BIO-RAD LABORATORIES, INC..: NET SALES ,($MILLION)

FIGURE 43.MERCK KGAA, DARMSTADT, GERMANY.: NET SALES ,($MILLION)

FIGURE 44.PERKINELMER INC..: NET SALES ,($MILLION)

FIGURE 45.SHIMADZU CORPORATION.: NET SALES ,($MILLION)

FIGURE 46.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)

FIGURE 47.QUANTERIX.: NET SALES ,($MILLION)

FIGURE 48.NEUROBIO.: NET SALES ,($MILLION)

FIGURE 49.BIOMÉRIEUX.: NET SALES ,($MILLION)

FIGURE 50.MYRIAD RBM (MYRIAD GENETICS, INC.).: NET SALES ,($MILLION